ArticleBioMed research international2020
Effectiveness and Safety of Botulinum Toxin Type A in the Treatment of Androgenetic Alopecia.
Article in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05456087 (Use of Botulinum Toxin in the Treatment of Androgenic Alopecia), which is not on this map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Use of Botulinum Toxin in the Treatment of Androgenic Alopecia
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- "Effectiveness of minimally invasive injectable modalities in the management of androgenetic alopecia among adults-A systematic review".Journal of cosmetic dermatology · 2024Pooled it
- Use of Botulinum Toxin for Androgenic Alopecia: A Systematic Review.Skin appendage disorders · 2022Pooled it
- Pooled it
- Efficacy and safety of topical finasteride spray solution in the treatment of Chinese men with androgenetic alopecia: A phase III, multicenter, randomized, double-blind, placebo-controlled study.Chinese medical journal · 2026Trial
- Assessing the efficacy and quality of Life improvements of botulinum toxin type a with topical minoxidil versus topical minoxidil in male androgenetic alopecia: a randomized controlled trial.Archives of dermatological research · 2024Trial
- Efficacy of type A botulinum toxin treatment for androgenetic alopecia using ultrasound combined with trichoscopy.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Trial
- Intradermal Botulinum Toxin A Injection for Scalp Sebum Secretion Regulation: A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Prospective Study in Chinese Subjects.Aesthetic surgery journal · 2023Trial
- Review
- Updates in Treatment for Androgenetic Alopecia.Annals of dermatology · 2025Review
- Botulinum Toxin in the Treatment of Hair and Scalp Disorders: Current Evidence and Clinical Applications.Toxins · 2025Review
- Androgenetic Alopecia: An Update on Pathogenesis and Pharmacological Treatment.Drug design, development and therapy · 2025Review
- Evaluation of the safety and efficacy of concentrated growth factors for hair growth promotion in androgenetic alopecia patients: A retrospective single-centre, single-arm study.Journal of cosmetic dermatology · 2024Article
- Study on botulinum toxin in dermatology from 2000 to 2023: A CiteSpace-based bibliometric analyses.Journal of cosmetic dermatology · 2024Review
- Clinical and preclinical approach in AGA treatment: a review of current and new therapies in the regenerative field.Stem cell research & therapy · 2024Review
- Review
- Intradermal Injection in Balding Region Versus Intramuscular Injection in Surrounding Muscles: A Split-Scalp, Randomized Trial on BoNT for Androgenetic Alopecia.Dermatology and therapy · 2024Article
- Efficacy and safety of botulinum toxin A in the treatment of female pattern hair loss.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Article
- Botulinum Toxin Type A Alleviates Androgenetic Alopecia by Inhibiting Apoptosis of Dermal Papilla Cells via Targeting circ_0135062/miR-506-3p/Bax Axis.Aesthetic plastic surgery · 2024Article
- Botulinum Toxin A for Hair Loss Treatment: A Systematic Review of Efficacy, Safety, and Future Directions.JPRAS open · 2023Review
- Comparing Current Therapeutic Modalities of Androgenic Alopecia: A Literature Review of Clinical Trials.Cureus · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAndrogenetic alopecia (AGA) represents the most frequent clinical complaint encountered by dermatologists and is characterized by a progressive miniaturization of the hair follicle. However, the efficacy and safety of current medical treatment remain limited, and more personalized therapeutic approaches for AGA are needed. Therefore, the present study is aimed at investigating the efficacy and safety of botulinum toxin type A (BTA) in patients with AGA.
methods63 patients with AGA meeting the inclusion criteria were included in this study and treated with BTA injection or BTA injection combined with oral finasteride (FNS). In the scalp, 30 sites were injected with 100 U of BTA in each site and patients received BTA after every 3 months for a total of 4 times. Hair counts, head photographs, evaluation scores, and self-assessment were assessed in patients with AGA.
resultsHair counts in both groups at all time points were significantly higher as compared with those before treatment. After 4 times of treatment, hair counts in the BTA+FNS group were higher than those in the BTA group. Hair growth and density were significantly augmented, and the area of hair loss was attenuated after each treatment as revealed by head photographs. The effective rates of BTA and BTA+FNS groups were 73.3% and 84.8%, respectively, following 4 times treatment.
conclusionBTA is a safe and effective therapeutic strategy for the treatment of AGA without adverse effects, and BTA combined with FNS exhibited a superior therapeutic effect than BTA alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.